| Cell line name |
LNCaP C4-2B MDVR |
|---|
| Synonyms |
C4-2B MDVR; LNCaP C4-2B MR; C4-2B MR |
|---|
| Accession |
CVCL_F0L5 |
|---|
| Resource Identification Initiative |
To cite this cell line use: LNCaP C4-2B MDVR (RRID:CVCL_F0L5) |
|---|
| Comments |
Population: Caucasian.
Characteristics: Resistant to 20 mmol/L of enzalutamide (PubMed=24740322).
Selected for resistance to: ChEBI; CHEBI_68534; Enzalutamide (Xtandi; MDV-3100).
Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
- Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
|
|---|
| Disease |
Prostate carcinoma (NCIt: C4863) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_4784 (LNCaP C4-2B) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
50Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=24740322; DOI=10.1158/1078-0432.CCR-13-3296; PMCID=PMC4058390
Cheng-Fei Liu, Wei Lou, Ye-Zi Zhu, Nagalakshmi Nadiminty, Chad T. Schwartz, Christopher P. Evans, Allen C. Gao;
Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Clin. Cancer Res. 20:3198-3210(2014) PubMed=28500234; DOI=10.1158/1535-7163.MCT-16-0912; PMCID=PMC5544572
Cheng-Fei Liu, Cameron M. Armstrong, Wei Lou, Alan P. Lombard, Vito Cucchiara, Xin-Wei Gu, Joy C. Yang, Nagalakshmi Nadiminty, Chong-Xian Pan, Christopher P. Evans, Allen C. Gao;
Niclosamide and bicalutamide combination treatment overcomes enzalutamide- and bicalutamide-resistant prostate cancer.
Mol. Cancer Ther. 16:1521-1530(2017) |
|---|
| Entry history |
|---|
| Entry creation | 14-Aug-2025 |
|---|
| Last entry update | 14-Aug-2025 |
|---|
| Version number | 1 |
|---|
